Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 to 60 years~2. Body mass index 20 kg/m2 to 27 kg/m2~3. Hemoglobin above 130g/L~4. Normal glucose tolerance in response to a 75g, 2-hr OGTT~Exclusion Criteria:~1. Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.~2. Any subject with active bleeding, bleeding diathesis, clotting abnormalities or recent surgery (within past 1 month)~3. Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \> 100 or systolic \> 180).~4. History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.~5. Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.~6. Any laboratory values: AST \> 2x ULN; ALT \> 2x ULN TSH \> 6 mU/l~7. Current addiction to alcohol or substances of abuse as determined by the investigator.~8. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation~9. Taking any prescription or non-prescription medications at the time of the study~10. Having donated blood three months prior to and three months post study procedures~11. A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.~12. Known allergy, hypersensitivity or contraindication to receiving study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- normal saline (Type: PLACEBO_COMPARATOR): normal saline intravenous infusion
- glucose (Type: ACTIVE_COMPARATOR): glucose intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).